Abstract
The present study aimed to explore immunological variables associated with survival, TP53 gene expression, and primary diagnosis in patients with cancer. Based on these variables, logistic regression and decision tree models (lightGBM) were used to model the probability of one-year survival of patients following their initial diagnosis. Logistic regression revealed the significance of primary diagnosis categories such as Malignant Melanoma, Ovarian Cancer, and Glioblastoma as predictor variables. For the classification model, in addition to these tumor types, variables related to the immune system were also found to be important, including tumor cell percentage, stromal cell percentage, lymphocytes, and necrotic cells. In addition, unsupervised classification techniques were employed to explore the numerical dataset. For this methodology, the best clustering cohesion was observed with two groups determined using different algorithms. The clusters generated by k-means and DBSCAN exhibited differences in the proportion of infiltrating lymphocytes, neutrophils, and monocytes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The results shown here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
